Abstract Details
10/10/2023 | 2:00 PM - 2:25 PM | 6613
What are the Prenatal Implications of Congenital Cytomegalovirus for the Provider and Patient?
Abstract Summary
OBJECTIVE: A considerable proportion of congenitally CMV infected infants will present with prenatal maternal evidence of infection. The diagnosis and evaluation of these mothers may not be evident to the non-obstetrician. METHODS: Collective experience of 2 obstetricians who have had active obstetric practices and extensive knowledge of maternal CMV infections and a developmental psychologist who has just completed a large prospective study on prenatal education and CMV screening. RESULTS: We will present our approach to the evaluation of the fetus when maternal CMV infection has been suspected or confirmed. A review of the literature on best practices for diagnostic testing and the clinical trials for treatment will also be provided. Lastly, we will present potential future directions to increase CMV awareness and to improve outcomes. CONCLUSION: Obstetric care for CMV infection is rapidly evolving. This aspect of CMV management has been understudied but will be crucial for the management of this challenging condition.
Learning Objectives
- Understand the current role for testing the pregnant mother for cytomegalovirus (CMV).
- Appreciate the recommended evaluation for the pregnant mother suspected to have CMV infection.
- Entertain future directions to enhance the evaluation and treatment of the pregnant mother with CMV infection.
Presentation
3440589_16123MarissaDiener.pdf
Handouts
No handouts have been uploaded.
Presenters
Marissa Diener | POC-Point of Contact, Primary Presenter, Co-Presenter
marissa.diener@fcs.utah.edu;
Marissa Diener, Ph.D., is a developmental psychologist and Professor at the University of Utah. Her research examines the impact of multiple factors, including child and parent factors and policies, on children's developmental outcomes. A study published in Pediatrics examined the impact of Utah's CMV law on CMV screening and children's diagnostic hearing evaluations. She is interested in the parenting experience and developmental outcomes of children with cCMV.
ASHA DISCLOSURE
Financial - No relevant financial relationship exists.
Nonfinancial - No relevant nonfinancial relationship exists.
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Albert Park | Co-Presenter, Author
albert.park@hsc.utah.edu;
Dr. Park is the chief for Pediatric Otolaryngology at the University of Utah. He is the principal investigator for an NIH funded multi-institutional clinical trial to determine whether the antiviral drug, valganciclovir can improve hearing outcomes for children with cytomegalovirus (CMV), a very common and understudied cause of childhood hearing loss.He also established a CMV working group comprising of pediatric genetics, infectious disease, otolaryngology, audiology, neurology, department of health and ARUP laboratories to streamline clinical and research initiatives in this field.
ASHA DISCLOSURE
Financial - No relevant financial relationship exists.
Nonfinancial - No relevant nonfinancial relationship exists.
AAA DISCLOSURE
Financial - No relevant financial relationship exists.
Nathan Blue | Co-Presenter, Author
nathan.blue@hsc.utah.edu;
Nathan R. Blue, MD, MSCI
Assistant Professor
Division of Maternal-Fetal Medicine
pronouns: he/him
University of Utah Department of Obstetrics and Gynecology
30 North 1900 East, 2B200
Salt Lake City, Utah 84132
801.581.8425
ASHA DISCLOSURE
Financial - Receives Grants for Other activities from Moderna.
Nonfinancial - No relevant nonfinancial relationship exists.
AAA DISCLOSURE
Financial - Receives support from Moderna for I am site PI for an mRNA CMV vaccine study..